SCHEMBL2652971

SCHEMBL2652971

Nc1cc(C2CCCCC2)ccc1Nc1cccc(-n2cccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 1/20 0.40
SYK P43405 1/20 0.38
MAPT P10636 5/20 0.37
HDAC1 Q13547 6/20 0.34
HDAC2 Q92769 5/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
LMNA P02545 1/20 0.33
XBP1 P17861 1/20 0.33
HTT P42858 1/20 0.33
BACE1 P56817 1/20 0.33
HDAC3 O15379 1/20 0.32
KMO O15229 1/20 0.32
ALDH1A1 P00352 5/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
POLB P06746 1/20 0.32
GAA P10253 5/20 0.32
KDM4E B2RXH2 3/20 0.32
GFER P55789 2/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2660340 0.87 SYK (0.43) TDO2SYKHDAC1
SCHEMBL2655213 0.83 SYK (0.43) TDO2SYKHDAC1LMNAMEN1
SCHEMBL2658767 0.81 L3MBTL1 (0.39) SYKMAPTSMN1; SMN2LMNAALDH1A1
SCHEMBL2652738 0.81 MAPT (0.37) SYKMAPTSMN1; SMN2ALDH1A1MEN1
SCHEMBL22453372 0.72 GAA (0.49) TDO2MAPTSMN1; SMN2LMNAXBP1
SCHEMBL2654297 0.70 SYK (0.41) TDO2SYKMAPTSMN1; SMN2LMNA
SCHEMBL2643607 0.70 HDAC2 (0.39) MAPTHDAC1HDAC2SMN1; SMN2LMNA
SCHEMBL2643366 0.69 ALK (0.40) MAPTHDAC2HTTHDAC3ALDH1A1
SCHEMBL2656336 0.69 ABL1 (0.41) SYKMAPTHDAC1LMNA
SCHEMBL21332384 0.68 KMO (0.51) TDO2MAPTHDAC2SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7335777-B2 Benzimidazole derivatives and their use for modulating the GABAA receptor complex NEUROSEARCH A/S (DK) 2008-02-26 US disclosed
US-20060148856-A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex ANIONA APS (DK) 2006-07-06 US disclosed
EP-1613312-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA sb A /sb RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2006-01-11 EP disclosed
WO-2004087137-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABAA RECEPTOR COMPLEX NEUROSEARCH A/S (DK) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148856-A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex GABRB2, GABRB1, GABRB3 TDO2 2196/4885SYK 3117/4885MAPT 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.